deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01785810

Phase II Maraviroc for GVHD Prevention

A Phase II Study to Assess the Efficacy of Maraviroc in Prophylaxis of GVHD in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic SCT From Unrelated Donors

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Hematologic Malignancy
Interventions Maraviroc 300 mg
Updated 13 times since 2017 Last updated: Dec 16, 2020 Started: Feb 28, 2013 Primary completion: Nov 11, 2016 Completion: Jul 12, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hematologic Malignancy and is currently completed. Abramson Cancer Center at Penn Medicine leads this study, which shows 13 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~May 2020 · 20 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2022 · 22 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~May 2023 · 4 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — May 2023 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 8 earlier versions

  1. Feb 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE2

  3. May 2020 — Jan 2021 [monthly]

    Completed PHASE2

  4. Sep 2018 — May 2020 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

  5. Jun 2018 — Sep 2018 [monthly]

    Unknown Status PHASE2

  6. Feb 2018 — Jun 2018 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  7. Feb 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations